UNSPSC 51112610: Nimustine hydrochloride

This classification denotes a nitrosourea compound with the molecular formula C9H13ClN6O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DFR965WKBU, chemically known as urea, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(2-chloroethyl)-n-nitroso- but more generally known as nimustine hydrochloride, which bears US NIH Compound Identifier 39214. European Medicines Agency schedules Nimustine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03435MIG.

UNSPSC 51112610 Nimustine hydrochloride, a Commodity code, covers procurement of this alkylating chemotherapy agent by state and local health systems, hospital networks, and cancer treatment facilities. Nimustine hydrochloride is a nitrosourea-class cytotoxic drug used in oncology protocols, typically sourced through pharmaceutical wholesalers or direct manufacturer channels as part of formulary acquisitions or emergency restocking under group purchasing organization (GPO) agreements or state pharmaceutical contracts. State Medicaid agencies, county health departments operating cancer centers, municipal hospitals, and academic medical centers with oncology services represent the primary purchasing bodies, though individual orders often flow through centralized GPO frameworks such as Vizient, MedAssets, or state-level cooperative purchasing vehicles that aggregate demand across multiple facilities. The code captures both routine pharmaceutical inventory replenishment and urgent refill solicitations when supplies fall below safety stock thresholds; purchasing typically occurs through ITB or standing-order RFQ processes rather than formal RFP cycles given the commodity nature of the product and established clinical protocols that govern dosing and supply patterns.

The source material contains no recent state and local procurement opportunities tagged to this Commodity code, and does not identify specific issuing bodies, response dates, geographic activity, or representative solicitations. This absence of recent posting activity may reflect the specialized and formulary-driven nature of oncology pharmaceutical procurement, which often operates through closed GPO frameworks or direct state pharmaceutical contracts rather than open competitive solicitations indexed in public databases.